FDA Approves Benlysta Autoinjector for Pediatric Patients With Active Lupus Nephritis

FDA approves Benlysta autoinjector for pediatric patients with active lupus nephritis

The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active lupus nephritis who are receiving standard therapy.

FDA Approves Benlysta Autoinjector for Pediatric Patients With Active ...

FDA Approves Benlysta Autoinjector for Pediatric Patients With Active Lupus Nephritis

MONDAY, June 30, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved an autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active lupus nephritis who are receiving standard therapy.

FDA news in pediatrics: June 2025

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from June 2025.

Comprehensive assessment of the association between genes on JAK-STAT pathway (IFIH1, TYK2, IL-10) and systemic lupus erythematosus: a meta-analysis

Previous studies have reported that genes relating to JAK-STAT pathway (IFIH1, TYK2 and IL-10) conferred the susceptibility to SLE. In this study, we perfo